Dr. Matthew Meyerson, MD, PhD, Associate Professor of Pathology at the Dana FarberCancer Institute and Senior Associate Member of the Broad Institute, recently published the results of his research project identifying somatic mutations in the CDKN1B gene among patients with small intestine neuroendocrine tumors. Dr. Meyerson’s results could lead to new treatment strategies for patients with this mutation. The findings, published in Nature Genetics, are the results of a carcinoid cancer genome project funded by the Caring for Carcinoid Foundation.
Dr. Meyerson’s team identified CDKN1B as a probable tumor suppressor suggesting that the mutation could lead to unregulated cell growth. This discovery could lead to new treatment strategies, including inhibitory therapies already being developed. Meyerson also found that carcinoid tumors have a very low mutation rate, which is similar to findings in pancreatic neuroendocrine tumors. We are encouraged by these recent findings and hope that our expanded knowledge might open the door to better treatment options for neuroendocrine tumor patients.
Read Dr. Meyerson’s Nature Genetics article.